REG - Syncona Limited - Issue of shares pursuant to incentive scheme

SynconaAnnouncement

15/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220715:nRSO5790Sa&default-theme=true

RNS Number : 5790S  Syncona Limited  15 July 2022

Syncona Limited

Issue of shares pursuant to incentive scheme and PDMR dealings

15 July 2022

Syncona Ltd (the "Company"), a leading healthcare company focused on founding,
building and funding a portfolio of global leaders in life science, today
announces that a total of 2,595,736 new ordinary shares (representing 0.39% of
the Company's existing issued ordinary shares) will be issued in satisfaction
of realisations under the Company's long term incentive scheme.  The new
ordinary shares, when issued, will rank pari passu with the existing issued
ordinary shares of the Company. In accordance with the rules of the incentive
scheme, the number of ordinary shares to be issued has been calculated using
the closing mid-market price on 13 July 2022, £1.964.

In accordance with the rules of the incentive scheme, ordinary shares
delivered on realisation may not be sold or transferred by the recipient for a
period of one year following the realisation date.

The issue of shares include the following shares to be issued to senior
members of the Syncona Investment Management Limited (SIML) leadership team:

 Name             SIML Title                No. of shares to be issued
 Martin Murphy    Chief Executive Officer   993,527
 Chris Hollowood  Chief Investment Officer  642,815

Application will be made to the Financial Conduct Authority for the shares to
be admitted to the Official List, and to the London Stock Exchange for the
shares to be admitted to trading and it is expected that dealings will
commence in the new ordinary shares on 20 July 2022.

Following admission, the Company will have 669,329,324 ordinary shares in
issue and the total number of voting rights in the Company will be
669,329,324. The Company does not hold any ordinary shares in treasury. This
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change in their interests in, the Company under the FCA's Disclosure and
Transparency Rules.

Notification of transactions by Persons Discharging Managerial
Responsibilities ("PDMRs") are set out below.

 ENDS 

Enquiries

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 7714 916615

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this
by founding and building companies to deliver transformational treatments to
patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science
to create a diversified portfolio of 15-20 globally leading healthcare
businesses, across development stage and therapeutic areas, for the benefit of
all our stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and management
teams. Our balance sheet underpins our strategy enabling us to take a
long-term view as we look to improve the lives of patients with no or poor
treatment options, build sustainable life science companies and deliver strong
risk-adjusted returns to shareholders.

Copies of this press release and other corporate information can be found on
the company website at: www.synconaltd.com (http://www.synconaltd.com)

 

 1.  Details of PDMR / person closely associated with them ("PCA")
 a)  Name                                     Martin Murphy
 b)  Position / status                        Chief Executive Officer, SIML
 c)  Initial notification / amendment         Initial Notification
 2.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary shares

                                              GG00B8P59C08
 b)  Nature of the transaction                Issue of shares pursuant to the Syncona long term incentive scheme
 c)  Price(s) and volume(s)                   Price(s)  Volume(s)

                                              £1.964    993,527
 d)  Aggregated information

     Aggregated volume

     Price                                    N/A
 e)  Date of the transaction                  14 July 2022
 f)  Place of the transaction                 Outside a trading venue
 g)  Currency                                 GBP - British Pound

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

14 July 2022

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

 1.  Details of PDMR / person closely associated with them ("PCA")
 a)  Name                                     Chris Hollowood
 b)  Position / status                        Chief Investment Officer, SIML
 c)  Initial notification / amendment         Initial Notification
 2.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary shares

                                              GG00B8P59C08
 b)  Nature of the transaction                Issue of shares pursuant to the Syncona long term incentive scheme
 c)  Price(s) and volume(s)                   Price(s)  Volume(s)

                                              £1.964    642,815
 d)  Aggregated information

     Aggregated volume

     Price                                    N/A
 e)  Date of the transaction                  14 July 2022
 f)  Place of the transaction                 Outside a trading venue
 g)  Currency                                 GBP - British Pound

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

14 July 2022

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEUSRORUWUBAUR